Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.
用于治疗重度抑郁症成人患者。
Centrum Badan Klinicznych PI-House Sp. z o.o., Gdańsk, Poland
Samodzielny Publiczny Zaklad Opieki Zdrowotnej (SPZOZ) - Centrum Neuropsychiatrii "NEUROMED", Wrocław, Poland
Clinic of Neurology and Psychiatry for Children and Adolescents, Belgrade, Serbia
CRTCE/KJK Healthplex, Toronto, Ontario, Canada
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
Novex Clinical Research, LLC, New Bedford, Massachusetts, United States
University of South Florida, Tampa, Florida, United States
the Massachusetts General Hospital, Boston, Massachusetts, United States
FI1041, Helsinki, Finland
EE1019, Tallinn, Estonia
FI1040, Helsinki, Finland
Cape Trial Centre, Bellville, Cape Town, South Africa
NHS Greater Glasgow and Clyde Glasgow Clinical Research Facility-Queen Elizabeth University Hospi..., Glasgow, United Kingdom
Hospital General Universitario Gregorio Maranon, Madrid, Spain
Rush University Medical Center, Skokie, Illinois, United States
US1386, Wichita, Kansas, United States
CO1004, Bogotá, Colombia
CO1002, Pereira, Colombia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.